ijms-logo

Journal Browser

Journal Browser

Advanced Technologies and Molecular Approaches in Brain Disease Diagnosis and Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 898

Special Issue Editor


E-Mail Website
Guest Editor
1. School of Food Science Environmental Health, Technological University Dublin, Dublin, Ireland
2. Nanolab Research Centre, Technological University Dublin, Dublin, Ireland
Interests: disease diagnostics and treatment; smart multifunctional molecular imaging nanoprobes; ultrasensitive detection technologies and devices; tumour biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases and brain cancer are  challenging human diseases heavily afflicting society. Nanotechnology is widely used in the fields of early diagnosis and drug delivery. This issue is dedicated to showing interdisciplinary research encompassing elements of medicine, biology, chemistry, physics, food science, and materials science. As a consequence of the increasing prevalence of neurodegenerative diseases, pain, and brain cancer and the low efficacy of current therapies, the development of treatment and diagnosis strategies have increased in the last years. Nanotechnology combining cold plasma, magnetic fields, and novel molecules can interact with biological systems at molecular levels with a high degree of specificity. This Special Issue will focus not only on neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia, chronic pain, and brain cancer,  but also on the impact of novel nanotechnology on earlier diagnosis and treatment.

Dr. Furong Tian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative diseases
  • brain cancer
  • nanotechnology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1336 KB  
Review
Molecular Biomarkers for Early Detection of Alzheimer’s Disease and the Complementary Role of Engineered Nanomaterials: A Systematic Review
by Muhammad Zia Ul Haq, Xinyi Zhao, Samuel Obeng Apori, Baljit Singh and Furong Tian
Int. J. Mol. Sci. 2025, 26(19), 9282; https://doi.org/10.3390/ijms26199282 - 23 Sep 2025
Viewed by 730
Abstract
Alzheimer’s disease (AD) instantly requires affordable diagnostic tools for targeting the responsible molecular biomarkers. In this review, we briefly discussed the overview of the AD population, performance of different analytical techniques and nanoparticles/composites, molecular biomarkers, and the interest of countries towards the detection [...] Read more.
Alzheimer’s disease (AD) instantly requires affordable diagnostic tools for targeting the responsible molecular biomarkers. In this review, we briefly discussed the overview of the AD population, performance of different analytical techniques and nanoparticles/composites, molecular biomarkers, and the interest of countries towards the detection of AD biomarkers during 2012–2025. The desired result was attained by lateral flow assay, surface-enhanced Raman scattering, and colorimetric sensor techniques with nanoparticles of magnetic, gold, and carbon-containing silver, and iridium oxide nanoparticles, upon biomarkers of dopamine, amyloid beta41, and Apolipoprotein E, individually. Additionally, the outstanding performance of nanoparticles including gold nanoparticles, carbon-containing nanoparticles, and manganese dioxide with their particle size of 5.7 nm, 35 nm, 37.3 nm, 120 nm, and 220 nm, respectively, has been discussed. Moreover, the percentages of AD-related biomarkers including amyloid beta42 having research articles of 21.2%, amyloid beta1-42 12.1%, amyloid beta oligomer 12.1%, phosphorylated Tau detection 12.1%, amyloid beta1-40 9.09%, Dopamine 9.09%, amyloid beta40 9.17%, apolipoprotein 6.06%, etc., have also been included. Additionally, LOD comparison with respect to applied analytical techniques, investigated through a timeline and electrochemical sensor, was found most suitable. Finally, a portable molecular diagnostic device to combine amyloid beta1-42, amyloid beta1-40, and phosphorylated Tau detection in non-invasive bodily fluid was proposed for the future and clinical diagnosis. Full article
Show Figures

Graphical abstract

Back to TopTop